EUCTR2018-001461-16-DE进行中（未招募）1 期
A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants with Hematologic Malignancies - MK-4280 and Pembrolizumab in Hematologic Malignancies
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 84
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Have measureable disease, defined as at least 1 lesion that can be accurately measured in 2 dimensions with diagnostic quality cross sectional anatomic imaging (CT or MRI). Minimum measurement must be >15 mm in the longest diameter or >10 mm in the short axis
- •2. Be able to provide a core or excisional tumor biopsy for biomarker analysis from an archival (within 3 months) or newly obtained biopsy (within 3 months) at Screening
- •PD-1/L1-Naive R/R cHL (Cohort 1)
- •3. Have histologically confirmed classical Hodgkin lymphoma
- •4. Have relapse (defined as disease progression after most recent therapy) or refractory (defined as failure to achieve CR or PR to most recent therapy) cHL and meet at least 1 of the following inclusions:
- •a.Have failed to achieve a response or progressed after autologous stem cell transplant.
- •b.Were unable to achieve a CR or PR to salvage chemotherapy and therefore did not proceed to auto- SCT, or were ineligible for auto-SCT due to age/co-morbidities as judged by treating physician.
- •5. Have not previously been treated with an anti-PD-1 or anti-PD-L1 therapy
- •PD-1/L1-Refractory R/R cHL (Cohort 2 and Cohort 5)
- •6. Have histologically confirmed classical Hodgkin lymphoma
- •7. Have relapsed (defined as disease progression after most recent therapy) or refractory (defined as failure to achieve CR or PR to most recent therapy) cHL and meet 1 of the following inclusions:
- •a.Have failed to achieve a response or progressed after auto-SCT.
- •b.Were unable to achieve a CR or PR to salvage chemotherapy and therefore did not proceed to auto -SCT, or were ineligible for auto-SCT due to age/co-morbidities as judged by treating physician.
- •8. Have progressed on treatment with an anti-PD-1/L1 mAb administered either as monotherapy or in combination with other checkpoint inhibitors or other therapies. PD-1 treatment progression is defined by meeting all of the following criteria:
- •a.Have received at least 2 doses of an anti-PD-1 mAb that has been approved in Hodgkin's lymphoma, with the agent administered at the approved dose and schedule
- •b.Have demonstrated disease progression after anti-PD-1/L1 as defined by Lymphoma Disease Response criteria. This determination is made by the investigator
- •c.Progressive disease has been documented within 12 weeks from the last dose of anti-PD- 1/L1 mAb
- •9. Have submitted pretrial imaging
- •R/R DLBCL (Cohort 3)
- •10. Have a histologically confirmed diagnosis of DLBCL. Transformed DLBCL, Gray zone lymphoma, Double hit lymphoma, PMBCL , T-cell histiocyte rich, EBV+ DLBCL, Alk positive, primary testicular DLBCL are permitted.
- •11. Must have progressed following at least 2 lines of previous therapy, including progression after an auto-SCT, have declined SCT, or are not a candidate (per institutional criteria) for an auto-SCT. Participants who are ineligible for standard treatment or who have withdrawn from standard treatment before disease progression due to unacceptable toxicity warranting discontinuation of that treatment and precluding retreatment with the same agent will also be eligible. R/R-iNHL (Cohort 4)
- •12. Have histologically confirmed diagnosis of indolent (low-grade) Bcell lymphoma, defined as FL, marginal zone lymphoma, mucosaassociated lymphoid tissue lymphoma, or small lymphocytic lymphoma (not associated with CLL). ymphoplasmacytic lymphomas, Waldenstrom's macroglobulinema, CLL, and T-cell lymphomas are not eligible.
- •13. Participants must have progressed following at least 2 lines of previous therap
排除标准
- •1. Has known clinically active central nervous system involvement
- •2. A WOCBP who has a positive urine pregnancy test within 72 hours
- •prior to study intervention allocation. If the urine test is positive or
- •cannot be confirmed as negative, a serum pregnancy test will be
- •3. Has known clinically significant heart disease
- •4. Has received prior therapy with an anti-LAG-3 antibody
- •5. Cohorts 1, 2, 3, 5: Has received CAR-T cell therapy
- •6. Cohort 1: Has received prior therapy with an anti-PD-1 or anti-PD-L1 antibody
- •7. Cohorts 2, 3, 4, 5: Has severe hypersensitivity (=Grade 3) to pembrolizumab and/or any of its excipients
- •8. Has received prior anticancer therapy or thoracic radiation therapy within 14 days before the first dose of study intervention
- •9. Grade 2 or higher nonhematological residual toxicities from prior therapy. Residual toxicity of Grade 1 from prior therapy or persistent
- •treatment-related Grade 1 neurotoxicity will be allowed
- •10. Has had a prior anticancer monoclonal antibody within 4 weeks prior to study Day 1 or who has not recovered (ie, =Grade 1 or at baseline) from AEs due to agents administered more than 4 weeks earlier
- •11. Has received a live vaccine within 30 days prior to first dose. Administration of killed vaccines are allowed.
- •12. Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 28 days before study Day 1
- •Diagnostic Assessment
- •13. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug
- •14. Has a known additional malignancy that is progressing or requires active treatment within the past 3 years.
- •15. Has active autoimmune disease that has required systemic treatment in past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed
- •16. Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis
- •17. Has an active infection requiring intravenous systemic therapy
- •18. Has a known history of human immunodeficiency virus (HIV) infection. No HIV testing is required unless mandated by local health authority
- •19. Has known, active hepatitis B (hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (hepatitis C virus [HCV] RNA [qualitative] is detected). No testing for Hepatitis B and Hepatitis C is required unless mandated by local health authority
- •20. Has a known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the study
- •21. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study intervention
- •22. Has had an allogeneic hematopoetic stem cell/solid organ transplantation within the last 5 years. (Participants who have had a transplant greater than 5 years ago are eligible as long as there are no symptoms of Graft versus Host Disease)
研究者
相似试验
招募中
1 期
MK-4280 and Pembrolizumab in Hematologic MalignanciesCTIS2023-503587-17-00Merck Sharp & Dohme LLC140
进行中（未招募）
1 期
MK-4280 and Pembrolizumab in Hematologic MalignanciesHematologic malignanciesMedDRA version: 21.1Level: LLTClassification code 10025315Term: Lymphoma malignantSystem Organ Class: 100000004864EUCTR2018-001461-16-ITMERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.84
已完成
2 期
Investigator-initiated Phase 2 clinical study of S-005151 in patients with osteoarthritis of the kneeOsteoarthritis of the kneeJPRN-jRCT2021200034Ishibashi Yasuyuki20
进行中（未招募）
1 期
A Phase II Pilot Study to Assess Safety and Efficacy of Sodium Valproate in Adults with McArdle DiseaseMcArdle disease (Glycogen storage disease type V, GSDV). The condition is an inherited disorder of skeletal muscle that causes exercise intolerance. The condition can give way to potential rhabdomyolysis which can cause acute renal failure and from middle age muscle wasting and weakness. Affected patients are unable to produce lactate during ischaemic exercise due to a congenital lack of the enzyme muscle glycogen phosphorylase which is essential for glycogen metabolism.MedDRA version: 16.1 Level: LLT Classification code 10026969 Term: McArdle's disease System Organ Class: 100000004850EUCTR2012-002933-12-GBniversity College London,8
进行中（未招募）
不适用
Study of a new drug combination to treat Chronic Lymphocytic Leukemiantreated or Relapsed Chronic Lymphocytic LeukaemiaMedDRA version: 14.1Level: LLTClassification code 10008968Term: Chronic lymphocytic leukaemia stage A(0)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-005178-43-ITGLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.80